Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors
NCT00568750
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
47
Enrollment
OTHER
Sponsor class
Conditions
Gastrointestinal Stromal Tumor
Interventions
DRUG:
dasatinib
Sponsor
Swiss Cancer Institute